Loading...

© 2026 MedXY

Contact us About us Privacy Policy MedXY story

MedXY News - immunotherapy

MedXY AI/MedXY News/Tag: immunotherapy

MedXY News

EnglishTag

immunotherapy

155 · 20 / page

Ask MedXY AI

type 2 diabetes clinical trial heart failure immunotherapy obesity atrial fibrillation cardiovascular risk biomarkers Cardiology clinical trials critical care Hypertension oncology public health artificial intelligence Alzheimer's disease breast cancer diabetes type 1 diabetes cardiovascular disease chronic kidney disease nutrition

Latest news

Tag

Cost-Effectiveness of Perioperative Pembrolizumab in Head and Neck Cancer: Impact of PD-L1 Expression Levels

newsCost-Effectivenessimmunotherapy

Cost-Effectiveness of Perioperative Pembrolizumab in Head and Neck Cancer: Impact of PD-L1 Expression Levels

By MedXY|Aug 11, 2026

The addition of perioperative pembrolizumab to standard care improves event-free survival in locally advanced head and neck squamous cell carcinoma, with cost-effectiveness dependent on PD-L1 combined positive score.

Pembrolizumab Combined with Radiotherapy Shows Promise in Advanced Cutaneous T-Cell Lymphoma: Final Results from UK NCRI Phase II Trial

Hematology-OncologyCutaneous T-Cell Lymphoma

Radiotherapy

Pembrolizumab Combined with Radiotherapy Shows Promise in Advanced Cutaneous T-Cell Lymphoma: Final Results from UK NCRI Phase II Trial

By MedXY|Aug 10, 2026

The UK NCRI phase II trial demonstrates pembrolizumab with localized radiotherapy yields meaningful response rates and durable control in relapsed/refractory advanced cutaneous T-cell lymphoma, marking an important step in improving outcome

Revolutionizing Classical Hodgkin Lymphoma Treatment: The Promise of Anti-PD-1 Therapy

Hematology-OncologyNivolumabimmunotherapy

Revolutionizing Classical Hodgkin Lymphoma Treatment: The Promise of Anti-PD-1 Therapy

By MedXY|Aug 5, 2026

Anti-PD-1 therapy has transformed classical Hodgkin lymphoma management, demonstrating safety, feasibility, and durable efficacy across treatment settings—from relapsed/refractory disease to frontline therapy.

Multimodal C9-66 CAR-T Cell Therapy: A Promising Advance in Pancreatic Cancer Treatment

newsCAR-T Therapyimmunotherapy

Multimodal C9-66 CAR-T Cell Therapy: A Promising Advance in Pancreatic Cancer Treatment

By MedXY|Jul 16, 2026

This article reviews the development and preclinical evaluation of C9-66 CAR-T cell therapy targeting oncofetal chondroitin sulfate in pancreatic cancer, highlighting metabolic and microenvironmental optimizations that improve efficacy and

Distinct Immune Subtypes in Type 1 Diabetes: Implications for Disease Progression and Personalized Immunotherapy

Allergy & ImmunologyDisease ProgressionImmune Subtypes

Distinct Immune Subtypes in Type 1 Diabetes: Implications for Disease Progression and Personalized Immunotherapy

By MedXY|Jul 14, 2026

Two immunologically distinct, age-independent subtypes of new-onset type 1 diabetes demonstrate differing progression rates and therapeutic responses, offering a path toward tailored immunotherapies.

Evaluating Consolidative Thoracic Radiotherapy with Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: Insights from the Phase 2 TREASURE Trial

newsatezolizumabclinical trial

Evaluating Consolidative Thoracic Radiotherapy with Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: Insights from the Phase 2 TREASURE Trial

By MedXY|Jul 14, 2026

The Phase 2 TREASURE trial investigated the safety and efficacy of adding consolidative thoracic radiotherapy to atezolizumab maintenance in extensive-stage small cell lung cancer, revealing increased toxicity without survival benefit, unde

$CD7-Directed CAR-T Cell Therapy in Relapsed/Refractory CD7-Positive Acute Myeloid Leukemia: Clinical Advances and Future Perspectives$

Clinical Updatesacute myeloid leukemiaCD7 CAR-T

CD7-Directed CAR-T Cell Therapy in Relapsed/Refractory CD7-Positive Acute Myeloid Leukemia: Clinical Advances and Future Perspectives

By MedXY|Jul 13, 2026

This review synthesizes recent phase I trial data on CD7 CAR-T therapies in relapsed/refractory AML, highlighting promising safety, high response rates, challenges with antigen loss relapse, and avenues for future research.

Durvalumab Plus Chemotherapy Extends Survival in Advanced Biliary Tract Cancer: Insights from the TOPAZ-1 Trial Four-Year Post Hoc Analysis

GastroenterologyBiliary tract cancercisplatin

Durvalumab Plus Chemotherapy Extends Survival in Advanced Biliary Tract Cancer: Insights from the TOPAZ-1 Trial Four-Year Post Hoc Analysis

By MedXY|Jul 12, 2026

A four-year post hoc analysis of the TOPAZ-1 trial confirms that durvalumab combined with gemcitabine and cisplatin offers a long-term survival benefit with manageable safety as first-line treatment for advanced biliary tract cancer.

Strategic Sequencing of Systemic Therapies in Advanced Hepatocellular Carcinoma: Beyond the Second Line

GastroenterologyChất ức chế kinase tyrosinehepatocellular carcinoma

Strategic Sequencing of Systemic Therapies in Advanced Hepatocellular Carcinoma: Beyond the Second Line

By MedXY|Jun 28, 2026

This article reviews evolving therapeutic sequences in advanced hepatocellular carcinoma, highlighting the integration of immune-based combinations, tyrosine kinase inhibitors, liver function preservation, and the emerging multidimensional

Targeting NEK9 to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma by Reprogramming the Tumor Microenvironment

Gastroenterologyhepatocellular carcinomaimmunotherapy

Targeting NEK9 to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma by Reprogramming the Tumor Microenvironment

By MedXY|Jun 27, 2026

NEK9 upregulation in hepatocellular carcinoma promotes immune evasion by enhancing PD-L1 expression and recruiting suppressive myeloid cells. Novel NEK9 inhibitors synergize with PD-L1 blockade, remodeling the tumor microenvironment and imp

Immune Checkpoint Inhibitors Deliver Durable Responses in MSI-H Gastroesophageal Adenocarcinoma

GastroenterologydMMRgastroesophageal adenocarcinoma

Immune Checkpoint Inhibitors Deliver Durable Responses in MSI-H Gastroesophageal Adenocarcinoma

By MedXY|Jun 19, 2026

MSI-H/dMMR gastroesophageal adenocarcinoma showed high response rates to immune checkpoint inhibitors, including durable complete responses in locoregional disease that may support carefully selected nonoperative management.

Checkpoint Blockade Delivers Deep, Durable Responses in MSI-H Gastroesophageal Adenocarcinoma

GastroenterologydMMRgastroesophageal adenocarcinoma

Checkpoint Blockade Delivers Deep, Durable Responses in MSI-H Gastroesophageal Adenocarcinoma

By MedXY|Jun 19, 2026

This single-center cohort found high and durable checkpoint inhibitor responses in dMMR/MSI-H gastroesophageal adenocarcinoma, including complete responses in locoregional disease that may support carefully selected nonoperative management.

Long-Term Safety Signals Remain Reassuring in Type 1 Diabetes Immunotherapy Follow-up

Diabetes & EndocrinologyimmunotherapyLong-Term Safety

Long-Term Safety Signals Remain Reassuring in Type 1 Diabetes Immunotherapy Follow-up

By MedXY|Jun 19, 2026

Extended follow-up of participants from 14 randomized trials found no excess self-reported serious adverse outcomes after type 1 diabetes immunotherapy, supporting continued long-term surveillance.

Avelumab Plus Methotrexate in Low-Risk Gestational Trophoblastic Tumors: A Promising First-Line Signal From TROPHAMET

newsavelumabgestational trophoblastic tumors

Avelumab Plus Methotrexate in Low-Risk Gestational Trophoblastic Tumors: A Promising First-Line Signal From TROPHAMET

By MedXY|Jun 19, 2026

TROPHAMET found that first-line avelumab plus methotrexate achieved 96.2% hCG normalization in low-risk gestational trophoblastic tumors with manageable toxicity, no relapses at 41 months, and preserved fertility.

First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial

Hematology-Oncologyfirst-line treatmentimmunotherapy

First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial

By MedXY|Jun 7, 2026

Extended follow-up from ASTRUM-005 shows serplulimab plus chemotherapy improves long-term survival in untreated extensive-stage small cell lung cancer, with manageable safety and encouraging patient-reported outcomes.

Beyond Extrapolation: Immunotherapy Outcomes in Recurrent Vulvovaginal Carcinoma

newsimmune checkpoint inhibitorsimmunotherapy

Beyond Extrapolation: Immunotherapy Outcomes in Recurrent Vulvovaginal Carcinoma

By MedXY|May 29, 2026

This retrospective study found that immune checkpoint inhibitors produced modest overall benefit in recurrent vulvar and vaginal carcinoma, but a small subset of patients had durable responses lasting months.

Body Mass Index and Nutritional Status With Immunotherapy Response in Head and Neck Cancer

newsBMIhead and neck cancer

Body Mass Index and Nutritional Status With Immunotherapy Response in Head and Neck Cancer

By MedXY|May 20, 2026

In advanced head and neck squamous cell carcinoma, pretreatment weight loss and low prognostic nutritional index were linked to shorter progression-free survival after immunotherapy, while baseline BMI was not predictive.

Synergistic Protection of Pancreatic Beta Cells: GLP1-E2 and Low-Dose Anti-CD3 Combination Therapy in Autoimmune Diabetes

Clinical UpdatesBeta-cell Protectionclinical research

Synergistic Protection of Pancreatic Beta Cells: GLP1-E2 and Low-Dose Anti-CD3 Combination Therapy in Autoimmune Diabetes

By MedXY|May 20, 2026

Recent studies demonstrate that combining the beta-cell-targeted conjugate GLP1-E2 with low-dose anti-CD3 therapy significantly delays type 1 diabetes onset by simultaneously reducing immune infiltration and mitigating beta-cell cellular st

Immunotherapy Prescribing Patterns and Immune-Related Adverse Events in Head and Neck Cancer

newshead and neck cancerimmunotherapy

Immunotherapy Prescribing Patterns and Immune-Related Adverse Events in Head and Neck Cancer

By MedXY|Apr 27, 2026

A large claims-based study reveals pembrolizumab dominates immunotherapy prescribing for head and neck cancer, with minimal usage growth since FDA approval. Immune-related adverse events occurred in 41.2% of patients, linked to specific com

Perioperative Nivolumab Combined with Irreversible Electroporation Shows Antitumoral Effect in High-Risk BCLC A Hepatocellular Carcinoma: Results from the NIVOLEP Phase 2 Trial

Gastroenterologyablation therapyhepatocellular carcinoma

Perioperative Nivolumab Combined with Irreversible Electroporation Shows Antitumoral Effect in High-Risk BCLC A Hepatocellular Carcinoma: Results from the NIVOLEP Phase 2 Trial

By MedXY|Apr 14, 2026

The NIVOLEP phase 2 trial demonstrates that perioperative nivolumab (neoadjuvant and adjuvant) combined with irreversible electroporation achieves 70.6% one-year local recurrence-free survival in BCLC A HCC patients with high recurrence ris

Prev 1 2 3 8 Next

Ask MedXY AI

Most popular

Intimate Health

Five Benefits for Women Continuing Sexual Activity After Menopause

Intimate Health

Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

How often should a couple have sex?

Intimate Health

Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure

Intimate Health

What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities